论文部分内容阅读
目的研究质子泵抑制剂奥美拉唑联合胃动力药西沙必利对反流性食管炎的治疗作用。方法 74例反流性食管炎患者采用随机方法分成两组,每组37例,治疗组应用奥美拉唑20 mg口服2次/d,西沙必利5 mg口服3次/d。对照组西沙必利5 mg口服3次/d。治疗4周后观察临床症状消失率及治愈率。结果讨论奥美拉唑和西沙必利,对照组单用西沙必利,观察治疗前后患者的临床症状改善和内镜变化。结果治疗4周,治疗组与对照组的症状消失有效率分别为98%、55%(P<0.05)。内镜复查治疗组、对照组食管黏膜病损愈合总有效率分别为82.3%和54.2%,两组比较差异有统计学意义(P<0.05)。结论尽管反流性食管炎的主要病因为动力障碍,但其主要的治疗方法仍为抑制胃酸的分泌,奥美拉唑与西沙必利联合治疗对其有明显的疗效。联合用药临床疗效优于单用西沙必利。
Objective To study the therapeutic effect of proton pump inhibitor omeprazole combined with gastric motility drug cisapride on reflux esophagitis. Methods A total of 74 patients with reflux esophagitis were randomly divided into two groups (37 in each group). The treatment group was orally given omeprazole 20 mg orally twice daily and cisapride 5 mg orally three times daily. Control group cisapride 5 mg orally 3 times / d. After 4 weeks of treatment, the disappearance rate of the clinical symptoms and the cure rate were observed. The results of omeprazole and cisapride, the control group with cisapride alone, observed before and after treatment to improve the clinical symptoms and endoscopic changes. Results After 4 weeks of treatment, the effective rates of symptoms disappeared in the treatment group and the control group were 98% and 55%, respectively (P <0.05). The total effective rate of esophageal mucosal lesion healing in endoscopic retesting group and control group were 82.3% and 54.2%, respectively, with significant difference between the two groups (P <0.05). Conclusion Although the main cause of reflux esophagitis is dysmotility, the main treatment is still the inhibition of gastric acid secretion. The combination of omeprazole and cisapride has obvious curative effect. Clinical efficacy of combination therapy is better than cisapride alone.